Phil L’Huillier, CatalYm CEO
German biotech CatalYm raises $50M to flip weight loss target for cancer
GDF15 might sound familiar. It’s a protein that Amgen, Merck and Eli Lilly built analogs for in attempts to make new weight loss drugs. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
